Document:

ruby_Ex10_12_1

		

			Exhibit 10.12.1

		

		

			***Text Omitted and Filed Separately with the Securities and Exchange

		

		

			Commission. Confidential Treatment Requested Under

		

		

			17 C.F.R. §200.80(b)(4)

		

		
			 
		

		
			This SECOND AMENDMENT, effective as of July 25, 2018 (the “SECOND AMENDMENT EFFECTIVE DATE”), amends the Exclusive Patent License Agreement dated January 28, 2016, and First Amendment dated December 12, 2017 (the “LICENSE”), between the Whitehead Institute for Biomedical Research (“WHITEHEAD”) and Rubius Therapeutics, Inc. (“COMPANY”).
		

		
			WHEREAS, WHITEHEAD and COMPANY wish to modify Appendix A of the LICENSE;
		

		
			WHEREAS, WHITEHEAD is owner of certain SECOND AMENDMENT PATENT RIGHTS, as later defined herein, relating to [***],  “[***]”, by [***];
		

		
			WHEREAS, WHITEHEAD desires to have the PATENT RIGHTS developed and commercialized to benefit the public, and WHITEHEAD is willing to grant a license thereunder;
		

		
			WHEREAS, COMPANY desires to add such SECOND AMENDMENT PATENT RIGHTS to the LICENSE.
		

		
			NOW, THEREFORE, WHITEHEAD and COMPANY hereby agree as follows:
		

		
			Capitalized terms used herein and not defined herein shall have the respective meanings ascribed to such terms in the LICENSE.
		

		
			1.          The following (hereinafter the “SECOND AMENDMENT PATENT RIGHTS”) is included under the definition of PATENT RIGHTS and is added to Appendix A of the LICENSE:
		

		
			[***].
		

		
			Appendix A of the LICENSE is deleted in its entirety and replaced with the Appendix A of this SECOND AMENDMENT, attached hereto.
		

		
			2.          For the avoidance of doubt, per Section 6.3 of the LICENSE, payment of all fees and costs, including attorneys’ fees relating to the filing, prosecution, and maintenance of the SECOND AMENDMENT PATENT RIGHTS shall be the responsibility of COMPANY, whether such amounts were incurred before or after the SECOND AMENDMENT EFFECTIVE DATE. WHITEHEAD has incurred $[***] for such patent-related fees and costs as of [***].
		

		
			3.          The following is added to Section 10.1 of the LICENSE:
		

		
			10.1      WHITEHEAD represents that as of the SECOND AMENDMENT EFFECTIVE DATE, it is the owner of all right, title, and interest in and to [***] of the PATENT RIGHTS, and it has the lawful right to grant the rights as set forth in this Agreement.
		

		
			 
		

		
			 
		

		
			

		 

		

			***Confidential Treatment Requested***ACTIVE/99026277.1

		

 

		

			***Text Omitted and Filed Separately with the Securities and Exchange

		

		

			Commission. Confidential Treatment Requested Under

		

		

			17 C.F.R. §200.80(b)(4)

		

		

		
			 
		

		
			4.          As consideration for this SECOND AMENDMENT, COMPANY shall pay WHITEHEAD a case addition fee of [***] Dollars ($[***]) within [***] of the SECOND AMENDMENT EFFECTIVE DATE. This payment is nonrefundable.
		

		
			5.          The LICENSE, as amended hereby, is hereby ratified and confirmed in all respects and shall continue in full force and effect. The LICENSE will, together with this SECOND AMENDMENT, be read and construed as a single instrument. All other terms and conditions of the LICENSE are confirmed and remain in full force and effect. This SECOND AMENDMENT shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns.
		

		
			Signatures follow on the next page.
		

		
			 
		

		
			 
		

		
			

		 

		

			2

		

		

			***Confidential Treatment Requested***

		

 

		

			***Text Omitted and Filed Separately with the Securities and Exchange

		

		

			Commission. Confidential Treatment Requested Under

		

		

			17 C.F.R. §200.80(b)(4)

		

		

		
			 
		

		
			IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives.
		

			
					
						For WHITEHEAD

					
					
						    

					
					
						For COMPANY:

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Carla DeMaria

					
					
						 

					
					
						By:

					
					
						/s/ Torben Straight Nissen

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						Carla DeMaria

					
					
						 

					
					
						Name:

					
					
						Torben Straight Nissen

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Title:

					
					
						Director of Intellectual Property & Sponsored Programs

					
					
						 

					
					
						Title:

					
					
						President

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Date:

					
					
						July 31, 2018

					
					
						 

					
					
						Date:

					
					
						July 25, 2018

				

		
			 
		

		
			
		

		
			

		 

		

			***Confidential Treatment Requested***ACTIVE/99026277.1

		

 

		

			***Text Omitted and Filed Separately with the Securities and Exchange

		

		

			Commission. Confidential Treatment Requested Under

		

		

			17 C.F.R. §200.80(b)(4)

		

		

		
			 
		

		
			APPENDIX A
		

		
			List of Patent Applications and Patents
		

		
			[***].
		

		
			 
		

		
			 
		

		 

		

			***Confidential Treatment Requested***ACTIVE/99026277.1Exhibit 4.3

 

Summary of Lease Agreement by and
among Tefen Yazamut Ltd. and Medigus Ltd.

 

Note: this summary does not contain
a full or direct translation of the terms of the original Hebrew-language lease agreement, and is designated solely for the purpose
of providing a general presentation of such agreement.

 

On January 6, 2004, Tefen Yazamut Ltd. (the
“Lessor”) and Medigus Ltd. (the “Company”) entered into a lease agreement, as amended from
time to time, as further elaborated below.

 

		1.	Leased Premises:

 

Certain areas in building
number 7A located in the Omer Industrial Park.

 

Total square meters
of leased premises: approximately 807.

 

		2.	Term of Lease:

 

The premises are currently leased
until December 31, 2019.

 

		3.	Purpose of the Lease:

 

The premises are to be used
by the Company for the purpose of offices, laboratories and clean rooms.

 

		4.	Consideration:

 

In consideration for the leased
premises the Company will pay Lessor a total amount of NIS 24,670 + VAT, per month, linked to the Israeli consumer price index.
The consideration shall be paid by the Company on a monthly basis.

 

The Company has provided the
Lessor a deposit in the amount of NIS 45,000 for the purpose of guaranteeing its financial obligations under the lease agreement.

 

		5.	Termination of the
Lease Agreement:

 

The Lessor may immediately terminate
the lease agreement upon: (i) the transfer or assignment of the Company’s rights in the premises to a third party contrary
to the terms and conditions stipulated in the lease agreement; or (ii) the Company’s failure to pay any due amount to the
Lessor within thirty (30) days of its due date; or (iii) use of the premises for purposes others than those stipulated in the agreement;
or (iv) the Company creates a nuisance that may disturb the surrounding businesses.

 

		6.	Liability for Injury,
Damage or Loss:

 

		(a)	The Company shall be
liable for any injury, damage or loss caused by its act or omission in, or in connection with, the premises, to the body or property
of any person or corporation, including to the Company or its employees or the Lessor or any other party.

 

		(b)	The Company shall be
liable and indemnify its employees or any other party for the damages, losses or expenses incurred by them due to injuries caused
in relation with the Company’s activities in the premises and the Lessor shall not be liable for any such damages losses
or expenses.

 

		7.	Insurance and Indemnity:

 

The Company shall maintain such
standard practice insurance policies as required by any applicable law and as customary with respect to the Company’s operations.Exhibi 4.5

 

[*] Represents material that has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.

AMENDMENT NO. 1 TO LICENSE AGREEMENT

THIS AMENDMENT NO. 1 (“Amendment”) is entered into effective as of June 18th, 2018 (the “Amendment Effective Date”) by and between BioLineRx Ltd. (“BioLine”) and Wartner Europe BV (“Perrigo”).

PREFACE:

	A.	
BioLine and Perrigo entered into a License Agreement dated as of December 22, 2014 (the “Agreement”).

	B.	
The Parties now wish to amend certain provisions of the Agreement.

Now therefore, the Parties hereby agree as follows:

	1.	
Section 3.1 of the Agreement is hereby deleted in its entirety and replaced with the following:

		3.1          	a.          	With respect to the Licensed Products referred to in Section 7.2, in consideration for the exclusive license granted to Licensee under Section 2.1, for each Licensed Product unit sold by Licensee and its Sublicensees in a given calendar quarter, Licensee will pay Licensor an amount equal to [*].

		b.	
For the purpose of this Agreement, [*].

	2.	
Subsections (a) and (b) of Section 3.2 are hereby deleted in their entirety and replaced with the following: [*]

	3.	
Section 3.3 is hereby deleted in its entirety and not replaced.

	4.         	(a)         	In Section 4.1, the sentence “Licensor has the right to examine Records that were created within five (5) years of the date of Licensor’s request” is hereby amended to read “Licensor has the right to examine Records that were created within seven (7) years of the date of Licensor’s request.”

		(b)	
In Section 4.2, the reference to “five (5) years” in the second line is hereby amended to “seven (7) years.”

	5.	
In Section 7.2(a), [*]

	6.	
Following the Amendment Effective Date, if Perrigo desires to add one or more countries to the Territory, it shall notify BioLine of such desire, and the Parties shall negotiate in good faith as to whether and on what terms such country(ies) will be added to the Territory.

	7.	
Capitalized terms used but not defined herein shall have the meanings set out in the Agreement.  Except as otherwise specifically agreed in this Amendment, the existing terms of the Agreement shall remain in full force and effect.

	8.	
This Amendment shall be binding upon the parties once executed by all parties and shall enter into force and become effective as of the Amendment Effective Date first written above.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.

	
BioLineRx Ltd.

	
Wartner Europe BV

	
By:/s/ Philip Serlin

	
By:/s/ Christophe Van Damme

	Name: Philip Serlin	
Name: Christophe Van Damme

	
Title: Chief Executive Officer

	Title: Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]